SCHEMBL29857558

SCHEMBL29857558

Cn1c2ccncc2c2ccc(-c3ccc(N4CC(CCN5CCN(c6ccc7c(c6)C(=O)N(C6CCC(=O)NC6=O)C7=O)CC5)C4)nc3)cc21

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ BRD9 Q9H8M2 3/20 0.47
▸ CRBN Q96SW2 6/20 0.45
▸ ITK Q08881 4/20 0.44
▸ RAF1 P04049 2/20 0.43
▸ BTK Q06187 1/20 0.43
▸ EGFR P00533 6/20 0.41
▸ IL2 P60568 1/20 0.41
▸ CCNC P24863 1/20 0.41
▸ CDK8 P49336 1/20 0.41
▸ IRAK1 P51617 1/20 0.41
▸ NTRK3 Q16288 1/20 0.41
▸ HASPIN Q8TF76 1/20 0.41
▸ CDK19 Q9BWU1 1/20 0.41
▸ IRAK4 Q9NWZ3 1/20 0.41
▸ IRAK3 Q9Y616 1/20 0.41
▸ ERBB3 P21860 1/20 0.41
▸ ALK Q9UM73 1/20 0.40
▸ ERBB2 P04626 1/20 0.40
▸ ESR1 P03372 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27098573 1.00 BRD9 (0.47) BRD9CRBNITKRAF1BTK
SCHEMBL27099253 0.95 BRD9 (0.47) BRD9CRBNITKRAF1BTK
SCHEMBL27099297 0.93 BTK (0.46) BRD9CRBNITKRAF1BTK
SCHEMBL29857130 0.93 BTK (0.46) BRD9CRBNITKRAF1BTK
SCHEMBL27098366 0.91 EGFR (0.47) BRD9CRBNITKRAF1BTK
SCHEMBL29547756 0.91 EGFR (0.47) BRD9CRBNITKRAF1BTK
SCHEMBL27098552 0.91 BRD9 (0.43) BRD9CRBNITKRAF1BTK
SCHEMBL29857366 0.91 BRD9 (0.43) BRD9CRBNITKRAF1BTK
SCHEMBL29857101 0.91 EGFR (0.47) BRD9CRBNITKRAF1BTK
SCHEMBL27099317 0.91 EGFR (0.47) BRD9CRBNITKRAF1BTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12559486-B2 Tau-protein targeting compounds and associated methods of use ARVINAS OPERATIONS, INC. (US) 2026-02-24 — — US disclosed
US-20240217962-A1 TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2024-07-04 — — US disclosed
US-11912699-B2 Tau-protein targeting compounds and associated ARVINAS OPERATIONS, INC. (US) 2024-02-27 — — US disclosed
US-20220315575-A1 TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2022-10-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220315575-A1 TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE VHL, CRBN, MAPT BRD9 2148/4885CRBN 2/4885ITK 4201/4885
US-11912699-B2 Tau-protein targeting compounds and associated MAPT, VHL, CRBN BRD9 1284/4885CRBN 3/4885ITK 4166/4885
US-20240217962-A1 TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE VHL, CRBN, MAPT BRD9 2148/4885CRBN 2/4885ITK 4201/4885
US-12559486-B2 Tau-protein targeting compounds and associated methods of use UBQLN2, UBQLN1, CRBN BRD9 878/4885CRBN 3/4885ITK 4386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback